[1]
|
Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26, 259-271.
https://doi.org/10.1093/annonc/mdu450
|
[2]
|
Stanton, S.E. and Disis, M.L. (2016) Clinical Significance of Tu-mor-Infiltrating Lymphocytes in Breast Cancer. Journal for ImmunoTherapy of Cancer, 4, Article 59. https://doi.org/10.1186/s40425-016-0165-6
|
[3]
|
Kos, Z., Roblin, E., Kim, R.S., et al. (2020) Pitfalls in Assessing Stromal Tumor Infiltrating Lymphocytes (sTILs) in Breast Cancer. npj Breast Cancer, 6, Article No. 17.
|
[4]
|
《乳腺癌新辅助治疗的病理诊断专家共识(2020版)》编写组. 乳腺癌新辅助治疗的病理诊断专家共识(2020版) [J]. 中华病理学杂志, 2020, 49(4): 296-304.
|
[5]
|
Gao, Z.H., Li, C.X., Liu, M. and Jiang, J.Y. (2020) Predictive and Prognostic Role of Tumour-Infiltrating Lymphocytes in Breast Cancer Patients with Different Molecular Subtypes: A Meta-Analysis. BMC Cancer, 20, Article No. 1150. https://doi.org/10.1186/s12885-020-07654-y
|
[6]
|
Zhou, Y., Tian, Q., Wang, B.Y., Yang, J., Zhao, S.D. and Yang, J. (2021) The Prognostic Significance of TILs as a Biomarker in Triple-Negative Breast Cancer: What Is the Role of TILs in TME of TNBC? European Review for Medical and Pharmacological Scienc-es, 25, 2885-2897.
|
[7]
|
Hammerl, D., Martens, J.W., Timmermans, M., Smid, M., Trapman-Jansen, A.M., Foekens, R., Isaeva, O.I., Voorwerk, L., Balcioglu, H.E., Wijers, R., et al. (2021) Spatial Immunophenotypes Predict Response to An-ti-PD1 Treatment and Capture Distinct Paths of T Cellevasion in Triple Negative Breast Cancer. Nature Communications, 12, Article No. 5668. https://doi.org/10.1038/s41467-021-25962-0
|
[8]
|
Ademuyiwa, F.O., Chen, I., Luo, J., Rimawi, M.F., Hagemann, I.S., Fisk, B., Jeffers, G., Skidmore, Z.L., Basu, A., Richters, M., et al. (2021) Immunoge-nomic Profiling and Pathological Response Results from a Clinical Trial of Docetaxel and Carboplatin in Tri-ple-Negativebreast Cancer. Breast Cancer Research and Treatment, 189, 187-202.
https://doi.org/10.1007/s10549-021-06307-3
|
[9]
|
Gonzalez-Ericsson, P.I., Stovgaard, E.S., Sua, L.F., Reisenbich-ler, E., Kos, Z., Carter, J.M., Michiels, S., Le Quesne, J., Nielsen, T.O., Laenkholm, A.V., Fox, S.B., Adam, J., Bartlett, J.M., Rimm, D.L., Quinn, C., Peeters, D., Dieci, M.V., Vincent-Salomon, A., Cree, I., Hida, A.I., Balko, J.M., Haynes, H.R., Frahm, I., Acosta-Haab, G., Balancin, M., Bellolio, E., Yang, W., Kirtani, P., Sugie, T., Ehinger, A., Castaneda, C.A., Kok, M., McArthur, H., Siziopikou, K., Badve, S., Fineberg, S., Gown, A., Viale, G., Schnitt, S.J., Pruneri, G., Penault-Llorca, F., Hewitt, S., Thompson, E.A., Allison, K.H., Symmans, W.F., Bellizzi, A.M., Brogi, E., Moore, D.A., Larsimont, D., Dillon, D.A., Lazar, A., Lien, H., Goetz, M.P., Broeckx, G., El Bairi, K., Harbeck, N., Cimino-Mathews, A., Sotiriou, C., Adams, S., Liu, S.W., Loibl, S., Chen, I.C., Lakhani, S.R., Juco, J.W., Denkert, C., Blackley, E.F., Demaria, S., Leon-Ferre, R., Gluz, O., Zardavas, D., Emancipator, K., Ely, S., Loi, S., Salgado, R., Sanders, M. and In-ternational Immuno-Oncology Biomarker Working Group (2020) The Path to a Better Biomarker: Application of a Risk Management Framework for the Implementation of PD-L1 and TILs as Immuno-Oncology Biomarkers in Breast Cancer Clinical Trials and Daily Practice. The Journal of Pathology, 250, 667-684. https://doi.org/10.1002/path.5406
|
[10]
|
Savas, P., Salgado, R. and Loi, S. (2021) Seeing the Forest and the Tree: TILs and PD-L1 as Immune Biomarkers. Breast Cancer Research and Treatment, 189, 599-606. https://doi.org/10.1007/s10549-021-06287-4
|
[11]
|
Stanton, S.E., Adams, S. and Disis, M.L. (2016) Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncology, 2, 1354-1360.
https://doi.org/10.1001/jamaoncol.2016.1061
|
[12]
|
Ravelli, A., Roviello, G., Cretella, D., et al. (2017) Tu-mor-Infiltrating Lymphocytes and Breast Cancer: Beyond the Prognostic and Predictive Utility. Tumor Biology, 4, 1-8. https://doi.org/10.1177/1010428317695023
|
[13]
|
Denkert, C., Loibl, S., Noske, A., et al. (2010) Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clin-ical Oncology, 28, 105-113.
https://doi.org/10.1200/JCO.2009.23.7370
|
[14]
|
Mao, Y., Qu, Q., Zhang, Y., et al. (2014) The Value of Tumor In-filtrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. PLOS ONE, 9, e115103. https://doi.org/10.1371/journal.pone.0115103
|
[15]
|
Li, S., Zhang, Y., Zhang, P., et al. (2022) Predictive and Prognostic Values of Tumor Infiltrating Lymphocytes in Breast Can-cers Treated with Neoadjuvant Chemotherapy: A Meta-Analysis. Breast, 66, 97-109.
https://doi.org/10.1016/j.breast.2022.10.001
|
[16]
|
Foldi, J., Silber, A., Reisenbichler, E., et al. (1970) Neoadjuvant Durvalumab plus Weekly Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Triple-Negative Breast Cancer. npj Breast Cancer, 7, Article No. 9.
|
[17]
|
van den Ende, N.S., Nguyen, A.H., Jager, A., et al. (2023) Tri-ple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. International Journal of Molecular Sciences, 24, Article 2969. https://doi.org/10.3390/ijms24032969
|